文献速递其他结缔组织病

数据驱动方法发现RNA聚合酶III抗体和肌腱摩擦音可作为早期弥漫性硬皮病试验的富集工具

A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

研究基于1980-2015年匹兹堡大学早期弥漫性系统性硬化症患者队列,采用Kaplan-Meier分析、基于组的轨迹分析、多变量回归和分类树分析,识别出皮肤增厚进展速率、RNA聚合酶III抗体阳性和肌腱摩擦音存在为5年随访mRSS轨迹的预测因素,并应用于ASSET试验数据,显示调整RNAP3和TFR可减弱安慰剂组mRSS反应并识别CRISS显著差异。

要点

  • 皮肤增厚进展速率、RNAP3抗体阳性和肌腱摩擦音存在预测5年mRSS轨迹。
  • 调整RNAP3和TFR后ASSET安慰剂组mRSS反应减弱,尤其6个月时。
  • 调整RNAP3在6个月、TFR或RNAP3在12个月时CRISS评分差异显著。

核心结论

  • 调整RNAP3和TFR可预测mRSS轨迹并减弱ASSET安慰剂组mRSS下降,识别CRISS显著差异。
  • RNAP3尤其是改善早期弥漫性SSc试验设计的分层或富集方法。

研究设计与样本

  • 研究识别1980-2015年在匹兹堡大学首次就诊的早期弥漫性SSc患者,纳入标准为至少3次访视且第一年随访内至少两次mRSS评分。
  • 采用Kaplan-Meier分析、基于组的mRSS轨迹分析、多变量回归分析和分类树分析,并将结果应用于ASSET试验结局数据。

主要发现

  • 识别出403例病程<18个月和514例病程<36个月的患者,mRSS随访评分中位数为14次(四分位距8,25)。
  • 所有方法学方法均识别皮肤增厚进展速率、RNAP3抗体阳性和TFR存在为5年随访mRSS轨迹的预测因素。
  • 应用于ASSET数据时,调整RNAP3和TFR后安慰剂组mRSS反应减弱,尤其6个月时。
  • 调整RNAP3在6个月时、调整TFR或RNAP3在12个月时发现CRISS评分显著差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinical trials in early diffuse SSc have consistently shown a placebo group response with a declining modified Rodnan skin score (mRSS), with negative outcomes. Our objective was to identify strategies using clinical characteristics or laboratory values to improve trial design. METHODS: We identified early diffuse SSc patients first seen at the University of Pittsburgh from 1980-2015. Eligible patients had ≥3 visits, with at least two mRSS scores within the first year of follow-up. We performed Kaplan-Meier analyses, group-based trajectory analysis of mRSS scores, followed by multivariable regression analysis and classification tree analysis. We applied the results to the abatacept in early diffuse systemic sclerosis (ASSET) trial outcome data. RESULTS: We identified 403 patients with <18 months, and 514 with <36 months disease duration. The median number of mRSS follow-up scores was 14 (interquartile range 8, 25). All methodologic approaches identified skin thickness progression rate, RNA polymerase III (RNAP3) antibody positivity and presence of tendon friction rubs (TFR) as predictors of mRSS trajectory over 5 years of follow-up, and thereby as potential enrichment variables. When applied to the ASSET data, adjustment for both RNAP3 and TFR demonstrated reduction of the placebo mRSS response, particularly at 6 months. A significant difference in the ACR Composite Response Index in Systemic Sclerosis (CRISS) score was found with adjustment by RNAP3 at 6 months, and TFR or RNAP3 at 12 months. CONCLUSION: Adjustment for both RNAP3 and TFR predicts mRSS trajectory and diminished the mRSS decline in ASSET placebo group, and identified significant differences in CRISS. RNAP3, particularly, is a stratification or enrichment approach to improve early diffuse SSc trial design.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Domsic RT, Medsger TA, Gao S, et al. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials. Rheumatology (Oxford). 2023. PMID: 36031807. doi:10.1093/rheumatology/keac501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。